High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Schodel J, Grampp S, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69:646–657. doi:10.1016/j.eururo.2015.08.007
   PubMed Web of Science ®Google Scholar
• Feng D, Zhang F, Liu L, et al. SKA3 serves as a biomarker for poor prognosis in kidney renal papillary cell carcinoma. Int J Gen Med. 2021;14:8591–8602. doi:10.2147/IJGM.S336799
   PubMed Web of Science ®Google Scholar
• Alaghehbandan R, Przybycin CG, Verkarre V, et al. Chromophobe renal cell carcinoma: novel molecular insights and clinicopathologic updates. Asian J Urol. 2022;9:1–11. doi:10.1016/j.ajur.2021.11.010
   Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. J Clin Invest. 2019;129:442–451. doi:10.1172/JCI120855
   Web of Science ®Google Scholar
• Gu W, Gong L, Wu X, et al. Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway. Cell Death Discov. 2021;7:147. doi:10.1038/s41420-021-00525-w
   Web of Science ®Google Scholar
• Cuvillier O. The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. Transl Androl Urol. 2017;6:131–133. doi:10.21037/tau.2017.01.12
   Web of Science ®Google Scholar
• Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets. 2008;8:349–358. doi:10.2174/156800908785133132
   PubMed Web of Science ®Google Scholar
• Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–2254. doi:10.1056/NEJMoa1611406
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang G, Lai J, et al. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine. 2021;71:103542. doi:10.1016/j.ebiom.2021.103542
   Web of Science ®Google Scholar
• Li Z, Wang Q, Peng S, et al. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. Clin Transl Med. 2020;10:e191. doi:10.1002/ctm2.191
   Web of Science ®Google Scholar
• Wang H, Wang M, Wen Y, et al. Biphasic regulation of mesenchymal genes controls fate switches during hematopoietic differentiation of human pluripotent stem cells. Adv Sci. 2020;7:2001019. doi:10.1002/advs.202001019
   Web of Science ®Google Scholar
• Lv Q, Xiao W, Xiong Z, et al. Identification of candidate biomarker EMP3 and its prognostic potential in clear cell renal cell carcinoma. Front Biosci. 2021;26:1176–1190.
   Web of Science ®Google Scholar
• Shen S, Wang JW, Zheng BH, et al. The lnc-CITED2-2:1 inhibits metastasis via inhibiting CITED2 and epithelial-mesenchymal transition in gallbladder cancer. Clin Transl Med;2020. e116. doi:10.1002/ctm2.116
   Web of Science ®Google Scholar
• Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112–117. doi:10.1038/nature19796
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49. doi:10.1038/nature12222
   PubMedGoogle Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603. doi:10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Nallandhighal S, Vince R, Karim R, et al. Molecular characterization of clear cell renal cell carcinoma reveals prognostic significance of epithelial-mesenchymal transition gene expression signature. Eur Urol Oncol. 2022;5:92–99. doi:10.1016/j.euo.2021.10.007
   Web of Science ®Google Scholar
• Zhu C, Tong R, Jiang X, et al. DNTTIP1 is a prognostic biomarker correlated with immune infiltrates in hepatocellular carcinoma: a study based on the cancer genome atlas data. Front Genet. 2021;12:767834. doi:10.3389/fgene.2021.767834
   Web of Science ®Google Scholar
• Ding S, Gao Y, Lv D, et al. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway. EBioMedicine. 2022;81:104100. doi:10.1016/j.ebiom.2022.104100
   Web of Science ®Google Scholar
• Liu YJ, Zeng SH, Qian WH, et al. DNTTIP2 expression is associated with macrophage infiltration and malignant characteristics in low-grade glioma. Pharmgenomics Pers Med. 2022;15:261–275. doi:10.2147/PGPM.S356326
   PubMed Web of Science ®Google Scholar
• Goldman M, Craft B, Swatloski T, et al. The UCSC cancer genomics browser: update 2015. Nucleic Acids Res. 2015;43:D812–7. doi:10.1093/nar/gku1073
   PubMed Web of Science ®Google Scholar
• Xiao W, Chen K, Liang HG, et al. Identification of KIF20A as a tumor biomarker and forwarder of clear cell renal cell carcinoma. Chin Med J. 2021;134:2137–2139. doi:10.1097/CM9.0000000000001331
   Web of Science ®Google Scholar
• Meng X, Yuan H, Li W, et al. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer. IUBMB Life. 2021;73:1363–1377. doi:10.1002/iub.2560
   Web of Science ®Google Scholar
• Xiong Z, Xiong W, Xiao W, et al. NNT-induced tumor cell “slimming” reverses the pro-carcinogenesis effect of HIF2a in tumors. Clin Transl Med. 2021;11:e264. doi:10.1002/ctm2.264
   Web of Science ®Google Scholar
• Li W, Meng X, Yuan H, et al. M2-polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma. IUBMB Life. 2022;74:391–407. doi:10.1002/iub.2596
   Web of Science ®Google Scholar
• Itoh T, Fairall L, Muskett FW, et al. Structural and functional characterization of a cell cycle associated HDAC1/2 complex reveals the structural basis for complex assembly and nucleosome targeting. Nucleic Acids Res. 2015;43:2033–2044. doi:10.1093/nar/gkv068
   Web of Science ®Google Scholar
• Sawai Y, Kasamatsu A, Nakashima D, et al. Critical role of deoxynucleotidyl transferase terminal interacting protein 1 in oral cancer. Lab Invest. 2018;98:980–988. doi:10.1038/s41374-018-0070-3
   Web of Science ®Google Scholar
• Zhuang H, Chen Y, Sheng X, et al. Searching for a signature involving 10 genes to predict the survival of patients with acute myelocytic leukemia through a combined multi-omics analysis. PeerJ. 2020;8:e9437. doi:10.7717/peerj.9437
   Web of Science ®Google Scholar
• Fenouille N, Puissant A, Dufies M, et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010;70:9659–9670. doi:10.1158/0008-5472.CAN-10-2034
   Web of Science ®Google Scholar
• Chorzalska A, Ahsan N, Rao RSP, et al. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-kappaB pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018;12:630–647. doi:10.1002/1878-0261.12186
   Web of Science ®Google Scholar
• Wu DW, Wang YC, Wang L, et al. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics. 2018;8:1256–1269. doi:10.7150/thno.22048
   Web of Science ®Google Scholar
• Zhang P, Xing Z, Li X, et al. Tyrosine receptor kinase B silencing inhibits anoikisresistance and improves anticancer efficiency of sorafenib in human renal cancer cells. Int J Oncol. 2016;48:1417–1425. doi:10.3892/ijo.2016.3356
   Web of Science ®Google Scholar
• Fanini F, Bandini E, Plousiou M, et al. MicroRNA-16 restores sensitivity to tyrosine kinase inhibitors and outperforms MEK inhibitors in KRAS-mutated non-small cell lung cancer. Int J Mol Sci. 2021;23:22. doi:10.3390/ijms23010022
   Google Scholar
• Swiatek M, Jancewicz I, Kluebsoongnoen J, et al. Various forms of HIF-1alpha protein characterize the clear cell renal cell carcinoma cell lines. IUBMB Life. 2020;72:1220–1232. doi:10.1002/iub.2281
   Web of Science ®Google Scholar
• Pajdzik K, Wilamowski M, Zurawek D, et al. Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2 alpha and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line. IUBMB Life. 2020;72:1807–1818. doi:10.1002/iub.2331
   Web of Science ®Google Scholar
• Qiu B, Ackerman D, Sanchez DJ, et al. HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015;5:652–667. doi:10.1158/2159-8290.CD-14-1507
   PubMed Web of Science ®Google Scholar
• Wang W, Xie X, Zhou Z, et al. Expression analysis of MIST1 and EMT markers in primary tumor samples points to MIST1 as a biomarker of cervical cancer. Int J Gen Med. 2021;14:1293–1300. doi:10.2147/IJGM.S307367
   PubMed Web of Science ®Google Scholar
• Yin L, Li W, Xu A, et al. SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine. 2020;51:102596. doi:10.1016/j.ebiom.2019.12.005
   PubMed Web of Science ®Google Scholar
• Dong Z, Gao M, Li C, et al. LncRNA UCA1 antagonizes arsenic-induced cell cycle arrest through destabilizing EZH2 and facilitating NFATc2 expression. Adv Sci. 2020;7:1903630. doi:10.1002/advs.201903630
   Web of Science ®Google Scholar
• He K, Xie M, Li J, et al. CENPO is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma. Int J Gen Med. 2022;15:7493–7510. doi:10.2147/IJGM.S382234
   Web of Science ®Google Scholar
• Meng X, Yuan H, Li W, et al. Biomarker screening and prognostic significance analysis for renal cell carcinoma. Int J Gen Med. 2021;14:5255–5267. doi:10.2147/IJGM.S325347
   PubMed Web of Science ®Google Scholar
• Guan T, Yang X, Liang H, et al. Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1. J Cell Physiol. 2022;237:2992–3000. doi:10.1002/jcp.30763
   Web of Science ®Google Scholar
• Meng X, Li W, Yuan H, et al. KDELR2-KIF20A axis facilitates bladder cancer growth and metastasis by enhancing Golgi-mediated secretion. Biol Proced Online. 2022;24:12. doi:10.1186/s12575-022-00174-y
   Web of Science ®Google Scholar
• Lin Y, Gao X, Liu Z, et al. Effective treatment of low-grade myofibroblastic sarcoma with apatinib: a case report and literature review. Pharmgenomics Pers Med. 2022;15:573–582. doi:10.2147/PGPM.S359492
   PubMed Web of Science ®Google Scholar
• Bao Z, Cheng J, Zhu J, et al. Using weighted gene co-expression network analysis to identify increased MND1 expression as a predictor of poor breast cancer survival. Int J Gen Med. 2022;15:4959–4974. doi:10.2147/IJGM.S354826
   PubMed Web of Science ®Google Scholar
• Huang TT, Burkett SS, Tandon M, et al. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene. 2022;41(46):5020–5031. doi:10.1038/s41388-022-02491-8
   Web of Science ®Google Scholar
• Li Y, Wu M, Zhang L, et al. Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner. Cell Death Discov. 2022;8:402. doi:10.1038/s41420-022-01190-3
   Web of Science ®Google Scholar